Drugs / MK-4280
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03486873 | Aug 2018 → Aug 2043 expected | cancer, hematopoietic and lymphoid cell neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-09-25 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer merck.com ↗
At the final pre-specified analysis, the favezelimab and pembrolizumab fixed-dose combination did not demonstrate an improvement in OS compared to standard of care (regorafenib or TAS-102 [trifluridine and tipiracil hydrochloride]). |
| 2018-11-07 | Merck Sharp & Dohme LLC | Results Early Phase 1 Data from Merck’s Oncology Pipeline for Investigational Anti-LAG-3 Therapy (MK-4280) and Anti-TIGIT Therapy (MK-7684) to Be Presented at SITC’s 33rd Annual Meeting merck.com ↗
These early studies are providing valuable early insights into the anti-tumor activity for our investigational anti-LAG-3 and anti-TIGIT therapies in patients with advanced and metastatic cancer. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4280 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03486873 ↗ |
| Route | Intravenous | “MK-4280 800mg as IV infusion” NCT03486873 ↗ |